Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex

Sponsor
Rabin Medical Center
Study ID
NCT01338103
Status
Unknown

Conditions

  • Pemphigus

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.

Study Details

The purpose of this study is to determine whether Rituximab, in the same doses as used in rheumatoid arthritis patients, will benefit pemphigus patients. It also tests immune function via the Cylex assay in pemphigus patients before and after treatment with RItuximab.

Key Dates

Start date
Jan 31, 2010
Status verified
Mar 2011
Primary completion
Jun 30, 2012
Completion
Jun 30, 2012

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rituximab

Primary Outcome Measure

Complete or partial remission off treatment (based on the consensus statement for pemphigus) [ Time Frame: 6 months after treatment ]

Central Contacts

  • Daniel Mimouni, MD
    972-3-9376658